Chandan Healthcare Ltd
Chandan Healthcare Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
4 of 5 strong
The short version
The company expects more than 50% year-on-year top-line growth for the next three years, focusing solely on the diagnostics business after divesting the pharmacy segment. The company targets over 50% year-on-year top-line growth for the next three years, driven by extensive expansion across India.
From Chandan Healthcare Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- The company expects more than 50% year-on-year top-line growth for the next three years, focusing solely on the diagnostics business after divesting the pharmacy segment.
- Expansion from 3 to 15 states supports this growth, with several centers and labs under construction, expected to be operational within months.
- Franchise business is a key growth driver, targeting over 1,000 franchises this year and aiming for 3,000 in three years, potentially achieving the target earlier.
- Corporate, government, and B2C businesses are all expected to grow, with an aim for an approximate revenue mix of one-third each among B2C (franchise), B2B, and B2G segments to sustain healthy growth and margins.
- Comprehensive diagnostic centers and labs are expected to contribute significantly, with mature centers crossing INR10 crore annual revenue and franchise volumes increasing sample inflow.
Profitability & Margins
See what Chandan Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Major part of the current year's capex has already been invested, including acquisition of one center in April and ongoing construction of comprehensive diagnostic centers and labs.
- Plans to open eight comprehensive centers and more than five to six labs, along with two PET scans and one genome lab, to be completed before December 2026.
- Total additional capex expected of around INR 10 crores+, to be funded from internal accruals or debt if needed.
- No capital investment required for franchise model; franchisees invest their own capital (~INR 1 lakh) for computer and equipment, paying initial franchise fee (INR 25,000 to 1 lakh) to the company.
- Company’s strategic focus is on expanding diagnostics business, divesting pharmacy business to focus capital on diagnostics.
- The franchise business is expected to grow rapidly, with zero capex from the company and advance payments received from franchisees.
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Chandan Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Chandan Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹65 Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Chandan Healthcare Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Manipal Health Enterprises Ltd (Q1 FY27)
Volume-led growth with inpatient (IP) volumes up 39% and outpatient (OP) volumes up 26% year-on-year. Key concall takeaways from Manipal Health Enterprises…
- Fortis Healthcare Ltd (Q1 FY27)
IHH plans to increase its stake in Fortis to over 50% within 3-5 years, supporting long-term strategic growth. Key concall takeaways from Fortis Healthcare…
- Metropolis Healthcare Ltd (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
- Apollo Hospitals Enterprise Ltd (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…
Frequently Asked Questions
What were Chandan Healthcare Ltd Q1 FY27 results?
The company expects more than 50% year-on-year top-line growth for the next three years, focusing solely on the diagnostics business after divesting the pharmacy segment. The company targets over 50% year-on-year top-line growth for the next three years, driven by extensive expansion across India.
What is Chandan Healthcare Ltd share price analysis?
Chandan Healthcare Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 23.1 with a market cap of ₹606 Cr. Investors should review the full earnings analysis for detailed insights.
Is Chandan Healthcare Ltd planning capital expenditure?
Major part of the current year's capex has already been invested, including acquisition of one center in April and ongoing construction of comprehensive diagnostic centers and labs.
Keep Chandan Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.